Chinook Therapeutics Announces Upcoming Data Presentations and Investor Conference Call During the…
Additional data to be presented from the ongoing phase 1/2 study of BION-1301 in patients with IgA nephropathy, including biomarker and proteinuria reductions Several presentations on the atrasentan clinical program, including…